Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VIVITROL
- A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3004
- Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use Disorder
- Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep
- Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
- Bridging ED to Outpatient AUD Therapy With Naltrexone
- In Hospital IM Naltrexone: A Pilot Study
- Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
- Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections
- Pharmacokinetic Study of Vivitrol in Healthy Participants
- Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
- Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder
- Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
- Vivitrol Treatment for Cannabis Use Disorder
- Medication Maintenance Therapy in Community Pharmacy Settings
- Feasibility of Emergency Department Initiated Extended-Release Naltrexone for the Treatment of Alcohol Use Disorder
- Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
- Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD
- Evaluation of Intranasal Naltrexone and Naloxone
- OLANI PK/Safety Study in Healthy Volunteers
- Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
- Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery
- Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
- A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
- Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
- Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
- Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
- Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
- Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
- Medication-Assisted Treatment for Youth With Substance Use Disorders
- Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
- Alcohol Disorder hOsPital Treatment Trial
- Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
- The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism
- Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
- Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
- Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
- Naltrexone for Individuals of East Asian Descent
- Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
- Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
- Harm Reduction With Pharmacotherapy (HaRP)
- Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
- Nalrexone Facilitated Discontinuation of Buprenorphine
- Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care
- Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
- Extended Release Naltrexone for Opioid-Dependent Youth
- Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
- Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
- Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
- CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
- Pre-Release VIVITROL for Opioid Dependent Inmates
- The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
- Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT
- A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
- Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
- Cocaine Use Reduction With Buprenorphine
- Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
- Improved Strategies for Outpatient Opioid Detoxification
- Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
- Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
- ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)
- ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
- ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
- ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
- Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
- Pilot Study of Depot NTX in Homeless Veterans
- Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland
- Alcohol Pharmacotherapy for HIV+ Prisoners
- Dronabinol Naltrexone Treatment for Opioid Dependence
- Study of Naltrexone for Methamphetamine Addiction
- ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
- VIVITROL as a Treatment for Cocaine and Alcohol Dependence
- ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
- Extended-release Naltrexone for Alcohol Dependence in Primary Care
- Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
- Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders
- ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
- ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence
- Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
- Naltrexone & SSRI in Alcoholics With Depression/PTSD
- ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])
- ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
Clinical trials list
click for details